XML 57 R43.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Geographic Information and Concentrations (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
Risks and Uncertainties [Abstract] |
Schedule of Revenue by Geographic Areas | A summary of our revenue by geographic areas for the years ended December 31, 2023, 2022 and 2021, is as follows (in thousands):
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
United States (1) | $ | 83,276 |  |  | $ | 15,600 |  |  | $ | — |
International: |  |  |  |  |
Asia Pacific (2) | 41,121 |  |  | 36,527 |  |  | 10,084 |
North America (3) | 59 |  |  | 31 |  |  | 13 |
Total revenue | $ | 124,456 |  |  | $ | 52,158 |  |  | $ | 10,097 |
(1)Revenues from the United States are primarily comprised of amounts earned from sales of IBSRELA and XPHOZAH, as well as the upfront license fee from the METiS Agreement. (2)Revenues from Asia Pacific are primarily comprised of amounts earned in accordance with the 2017 Kyowa Kirin Agreement, the 2019 Kyowa Kirin Agreement and the Fosun Agreement. (3)Revenues from North America are comprised of amounts earned from Canada in accordance with the Knight Agreement.
Schedule of Revenues from Customers and Collaboration Partnerships | Revenue from the following Customers who contributed greater than 10% of our gross product revenue during the years ended December 31, 2023 and 2022 as a percentage of total gross product revenue was as follows:
|  |  | Year Ended December 31,
|  |  |  |  | 2023 |  | 2022
BioRidge Pharma, LLC |  |  |  |  | 26.3 | % |  | — | %
Cardinal Health |  |  |  |  | 21.6 | % |  | 23.1 | %
AmerisourceBergen Drug Corporation |  |  |  |  | 20.9 | % |  | 26.8 | %
McKesson Corporation |  |  |  |  | 17.2 | % |  | 21.6 | %
Revenues from Customers and collaboration partnerships accounting for more than 10% of total revenues during the years ended December 31, 2023, 2022 and 2021 were as follows:
| Year Ended December 31,
| 2023 |  | 2022 |  | 2021
Kyowa Kirin | 29.0 | % |  | 70.0 | % |  | 100.0 | %
Bioridge Phama | 24.0 | % |  | 3.2 | % |  | — | %
Cardinal | 19.8 | % |  | 9.6 | % |  | — | %
AmerisourceBergen Drug Corporation | 19.1 | % |  | 11.1 | % |  | — | %
McKesson | 15.7 | % |  | 8.9 | % |  | — | %

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph a -SubTopic 10 -Topic 280 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration